Bioverativ and DDB Health
See the Future
With sweet simplicity, this launch spoke to providers who treat hemophilia, encouraging them to look past short-term bleeding control to the long-term health of a child’s joints. Everyone can relate to the dreams of a child. By depicting pediatric patients early on, and then as what they might be like as grown-ups, Bioverativ Alprolix gained share, with a switch-capture of 21%.